Delcath Systems (NASDAQ:DCTH) Shares Climb 7.2% Following Strong Earnings

Delcath Systems, Inc. (NASDAQ:DCTH)’s share price rose 7.2% during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $21.84 and last traded at $21.7290. 533,561 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 468,296 shares. The stock had previously closed at $20.27.

The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.26. The firm had revenue of $35.10 million for the quarter, compared to the consensus estimate of $25.99 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Q3 results topped estimates: Delcath reported earnings of $0.17 per share versus analysts’ expected loss of about $0.09, while revenue of $35.1 million exceeded the $26.0 million consensus. Earnings also improved from $0.02 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Management guided to FY 2026 revenue of $115 million–$117 million, above the approximately $106.2 million analyst consensus. It also set a goal of having at least 36 active centers by year-end, supporting expectations for continued commercial expansion. Delcath revenue guidance and active-center target
• Positive Sentiment: HC Wainwright raised its price target to $36 from $32 and maintained a Buy rating. BTIG Research also raised its target, to $25 from $21, and kept its Buy rating—both moves signal stronger analyst confidence. HC Wainwright recommendations BTIG Research recommendations

Analysts Set New Price Targets

DCTH has been the subject of a number of research analyst reports. HC Wainwright upped their target price on Delcath Systems from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Tuesday. BTIG Research upped their target price on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Finally, Zacks Research cut Delcath Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.33.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its position in Delcath Systems by 31.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Delcath Systems by 30.3% in the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock worth $729,000 after purchasing an additional 10,600 shares in the last quarter. Kopp Family Office LLC acquired a new position in Delcath Systems during the third quarter valued at approximately $450,000. Integrated Wealth Concepts LLC bought a new stake in Delcath Systems during the second quarter valued at about $48,000. Finally, IFP Advisors Inc acquired a new position in Delcath Systems during the 2nd quarter valued at $52,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Price Performance

The company’s 50 day moving average is $15.53 and its two-hundred day moving average is $12.49. The firm has a market cap of $754.00 million, a P/E ratio of 2,170.67 and a beta of 0.62.

About Delcath Systems

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.